Cargando…

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation

INTRODUCTION: The association between abemaciclib dose reduction and treatment adherence is not clear. In this study, we examined real-world data of Japanese patients with advanced breast cancer (ABC) to determine how abemaciclib dose reduction is related to treatment continuation. METHODS: This ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Shinya, Maeda, Hideki, Umehara, Kengo, Kuwahara, Sayuri, Yamamoto, Mitsugu, Tomioka, Nobumoto, Takahashi, Masato, Watanabe, Kenichi, Hashishita, Hirokazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505863/ https://www.ncbi.nlm.nih.gov/pubmed/37378924 http://dx.doi.org/10.31557/APJCP.2023.24.6.1955

Ejemplares similares

Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
por: Tomioka, Nobumoto, et al.
Publicado: (2023)

Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
por: Tomioka, Nobumoto, et al.
Publicado: (2023)

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer
por: Takada, Shinya, et al.
Publicado: (2022)

Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Takada, Shinya, et al.
Publicado: (2020)

Abemaciclib for breast cancer
Publicado: (2020)

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
por: Takada, Shinya, et al.
Publicado: (2018)

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation
por: Torres-Guzmán, Raquel, et al.
Publicado: (2022)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
por: Masuda, Hiroko, et al.
Publicado: (2023)

Tsurumi ensures continued delivery capability
Publicado: (2020)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings
por: Okayasu, Kaori, et al.
Publicado: (2023)

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea
por: CAKCAK, İbrahim Ethem, et al.
Publicado: (2022)

Ensuring Emerging Themes in Epidemiology’s continued success
por: Coughlin, Steven S.
Publicado: (2021)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Molecular docking and machine learning analysis of Abemaciclib in colon cancer
por: Liñares-Blanco, Jose, et al.
Publicado: (2020)

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
por: Takahashi, Gary W, et al.
Publicado: (2022)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Association between Area under the Curve Estimated from Carboplatin Dose and Incidence of Severe Thrombocytopenia in Patients with Non-Hodgkin’s Lymphoma on DeVIC Therapy
por: Umehara, Kengo, et al.
Publicado: (2023)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis
por: Turner, Martin R, et al.
Publicado: (2015)

The mission to ensure continued funding for excellent basic research
por: Lamond, Angus I., et al.
Publicado: (2023)

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
por: Small, Jeffrey, et al.
Publicado: (2017)

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate
por: Chappell, Jill C., et al.
Publicado: (2018)

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics
por: Chigutsa, Emmanuel, et al.
Publicado: (2020)

Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer
por: Kurtyka, David J., et al.
Publicado: (2021)

Ensuring continued progress for development of COVID-19 therapeutics in children
por: Noel, Gary J., et al.
Publicado: (2021)

Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab
por: Chiba, Takeshi, et al.
Publicado: (2022)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
por: Di Leo, Angelo, et al.
Publicado: (2018)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ta6blivoour1qib94hcd7mcsqn